{"organizations": [], "uuid": "6a654d4b8efdb14ea082cf26fc9f87da3ea63d54", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.pharmamedtechbi.com", "main_image": "", "site_section": "http://feeds.feedburner.com/MedicalDeviceFinancing", "section_title": "Medical Device Financing from Elsevier Business Intelligence", "url": "https://www.pharmamedtechbi.com/deals/201530604?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)%2520and%2520(%2540dealtype%253d%2522Financing%2522)", "country": "US", "title": "Newly public ViewRay completes $26.7mm private placement", "performance_score": 0, "site": "pharmamedtechbi.com", "participants_count": 0, "title_full": "Newly public ViewRay completes $26.7mm private placement", "spam_score": 0.0, "site_type": "news", "published": "2015-08-04T02:40:00.000+03:00", "replies_count": 0, "uuid": "6a654d4b8efdb14ea082cf26fc9f87da3ea63d54"}, "author": "", "url": "https://www.pharmamedtechbi.com/deals/201530604?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d%2520(%2540industries%253d%2522Medical%2520Devices%2522)%2520and%2520(%2540dealtype%253d%2522Financing%2522)", "ord_in_thread": 0, "title": "Newly public ViewRay completes $26.7mm private placement", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "Newly public ViewRay completes $26.7mm private placement Deal Date: Jul-01-2015 / Deal # 201530604 Executive Summary \nConcurrent with a reverse merger that brought it a public listing on the OTCBB, MRI-guided radiation firm ViewRay Inc. completed a private placement of 5.3mm shares at $5 for gross proceeds of $26.7mm. New and existing buyers participated including Aisling Capital, Fidelity, Kearny Venture Partners, Montrose Capital, OrbiMed, and Xeraya Capital. Money will support continued commercialization of the MRIdian cancer radiation therapy system.", "external_links": [], "published": "2015-08-04T02:40:00.000+03:00", "crawled": "2015-08-04T17:01:37.357+03:00", "highlightTitle": ""}